CareDx Raises Revenue Guidance for 2026 and Reports Q2 Earnings Beat
CareDx (CDNA) reported better-than-expected second-quarter financial results, leading to a ~14% rise in its stock price on Friday. The company raised its revenue guidance for the year ending 2026 from $447M-$465M to $490M-$500M, surpassing both previous expectations and analyst consensus of $461.74M. The updated forecast reflects strong performance in key areas such as transplant monitoring services and product sales. The guidance increase signals confidence from management about the company's growth trajectory and market position within its sector.
Tickers: $CDNA
Topics: caredx cdna q2 results revenue guidance